Aslan Pharms Stock Price, News & Analysis

ASLAN Pharmaceuticals (NASDAQ: ASLN) announced two abstracts on eblasakimab accepted for poster presentation at the 1st International Societies for Investigative Dermatology Meeting from May 10 to 13, 2023, in Tokyo, Japan. The posters will discuss eblasakimab’s clinical efficacy in treating difficult areas for atopic dermatitis, focusing on itch alleviation and sensory nerve modulation.

Notable posters include results from a Phase 1 study showing symptom improvement in moderate-to-severe atopic dermatitis and findings on targeting IL-13Rα1. The company is conducting a Phase 2b trial (TREK-AD) to evaluate eblasakimab, with topline results expected in July 2023.

ASLAN Pharmaceuticals (Nasdaq: ASLN) announced a change in its American Depositary Shares (ADS) ratio on March 10, 2023. The new ratio will be one ADS representing twenty-five ordinary shares, effectively a one-for-five reverse ADS split. This change is set to take place on March 13, 2023, and existing ADS holders will see their holdings automatically converted without needing action. There will be no fractional new ADSs issued; fractional entitlements will be sold, and proceeds distributed to ADS holders. While the ADS price is expected to increase proportionally, ASLAN cannot guarantee that it will be five times the current price.

ASLAN Pharmaceuticals (Nasdaq: ASLN) announced a virtual research and development day on March 16, 2023. Key Opinion Leader Brett King, MD PhD, from Yale University, will discuss alopecia areata (AA) and its treatment challenges. Following this, ASLAN's leadership will present updates on farudodstat, an oral DHODH inhibitor currently in a Phase 2 proof-of-concept trial for AA, aimed to begin in Q2 2023. Farudodstat has shown promise in inhibiting immune cell activity and protecting hair follicles. A live Q&A will follow, and registration is available online.

ASLAN Pharmaceuticals (Nasdaq: ASLN) is advancing farudodstat, a potent oral DHODH inhibitor, into a Phase 2 proof-of-concept trial for alopecia areata (AA), targeting an unmet medical need. The trial is set to enroll approximately 60 patients in the US starting in Q2 2023, with interim results expected by Q1 2024. Farudodstat has shown significant potency and a favorable safety profile, being 30 times more effective than existing DHODH inhibitors in preliminary tests. The company is hosting a virtual R&D Day on March 16, 2023, to discuss the treatment landscape and unmet needs in AA.

ASLAN Pharmaceuticals (Nasdaq: ASLN) has entered a purchase agreement to secure $20 million in financing, with potential additional funding of up to $80 million, aimed at advancing the clinical development of eblasakimab and farudodstat.

This financing extends ASLAN's cash runway through at least Q2 2024. Proceeds will support the ongoing TREK-AD study and the upcoming farudodstat trial.

Investors will acquire 112,359,550 ordinary shares at $0.178 each, with warrants exercisable following the announcement of trial data. The financing is expected to close around February 27, 2023.

ASLAN Pharmaceuticals has completed patient enrollment for the TREK-AD study, a Phase 2b clinical trial evaluating eblasakimab in adults with moderate-to-severe atopic dermatitis. The final patient was enrolled on February 24, 2023, with topline results expected in early July 2023. This randomized, double-blind, placebo-controlled study includes primary endpoints focusing on the percentage change in the Eczema Area Severity Index (EASI) score. The study aims to establish eblasakimab's potential as a first-choice biologic treatment in atopic dermatitis, complementing ongoing research in other patient populations.

ASLAN Pharmaceuticals (Nasdaq: ASLN) has partnered with Thermo Fisher Scientific to manufacture a high concentration formulation of eblasakimab for upcoming Phase 3 clinical trials. This formulation allows for up to 400mg to be delivered via a single injection, enhancing its administration. Manufacturing will start in January 2023 in Thermo Fisher's GMP-certified facilities. ASLAN's ongoing trials include the TREK-AD and TREK-DX studies, with topline data anticipated in 2023 and 2024, respectively, positioning eblasakimab as a potential groundbreaking treatment for atopic dermatitis.

ASLAN Pharmaceuticals (Nasdaq: ASLN) has announced its participation in several key conferences in January 2023. These events, including the BIO Partnering Conference and the 12th Annual LifeSci Partners Corporate Access Event, aim to facilitate one-on-one meetings with investors. The company is also focusing on its clinical programs, particularly the Phase 2b trial for eblasakimab, targeting moderate-to-severe atopic dermatitis, with results expected in 2Q 2023. Additionally, ASLAN plans to initiate a Phase 2 trial for farudodstat in skin autoimmune diseases in the first half of 2023.

ASLAN Pharmaceuticals (ASLN) has initiated the TREK-DX study to evaluate eblasakimab in patients with atopic dermatitis previously treated with dupilumab. This Phase 2 trial will enroll 75 patients in North America, with topline results expected in Q1 2024. The study is fully funded, ensuring no impact on ASLN's cash runway. Eblasakimab aims to provide a differentiated efficacy and safety profile by directly blocking the IL-13 receptor, potentially benefiting patients who lack effective treatment options.